A unique portfolio of high quality and difficult-to-make pharmaceutical products fuels our targeted growth strategy. Alvogen has over 200 strategically selected pharmaceutical projects in development and registrations and 350 marketed products. The group’s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory, neurology and gastroenterology. Alvogen also sells and markets a growing portfolio of OTC medicines.
Alvogen has commercial operations in more than 30 countries around the globe. The company has an innate passion for performance and growth and has become a major player driving change in this ever-changing industry. Our passionate team is committed to continue to grow our business around the world and build a top 10 global generic pharmaceuticals player. North America is our largest market, where we have over 60 pending ANDA filings.
Alvotech, an independent sister company of Alvogen, today announces the opening of a new state-of-the-art facility, dedicated to the development and manufacturing of biosimilar monoclonal antibodies (“mAbs”).
Alvogen’s leadership team is dedicated to fostering a dynamic change-driven culture committed to meeting the needs of our customers. Our organizational structure is lean and flexible, driving quick and effective decision making and thus enabling the company to bring new generic products quickly and safely to market.
The executive leadership team forms the Alvogen Management Board, led by Robert Wessman Chairman & CEO.